27 June 2017

Japan’s GHIT Fund continues investment into pediatric praziquantel formulation

The Japanese Global Health Innovative Technology (GHIT) Fund announced that it will continue to support the Pediatric Praziquantel Consortium with an additional US$4.7 million. Having previously awarded US$6.76 million in 2014...

GHIT's mission is to facilitate international partnerships that bring Japanese innovation, investment, and leadership to the global fight against infectious diseases and poverty in the developing world. The Consortium’s clinical trial is one of the most advanced partnerships invested in by the GHIT Fund.

“The Pediatric Praziquantel Consortium is extremely pleased with the latest contribution from the GHIT Fund. It continues to be a significant partner in achieving our ambition to create a praziquantel formulation for every child suffering from schistosomiasis infection,” said Dr. Elly Kourany-Lefoll, Consortium Program Lead. 

Consortium partners Astellas and Merck were also very pleased to attend the GHIT Partners’ Annual Meeting on June 1st, 2017, at the occasion of the GHIT Fund 5th Anniversary. Further details on the funding and the pediatric praziquantel development program are highlighted in the GHIT Fund press release from 30 March, 2017.